US medical devices industry sees a drop of 17.1% in deal activity in December 2019

27 January 2020 (Last Updated January 27th, 2020 06:49)

US medical devices industry sees a drop of 17.1% in deal activity in December 2019

The US medical devices industry saw a drop of 17.1% in overall deal activity during December 2019, when compared with the last 12-month average, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

A total of 68 deals worth $2.54bn were announced in December 2019, compared to the 12-month average of 82 deals.

Venture financing was the leading category in the month in terms of volume with 50 deals which accounted for 73.5% of all deals.

In second place was M&A with 15 deals, followed by private equity with three transactions, respectively accounting for 22.1% and 4.4% of overall deal activity in the country’s medical devices industry during the month.

In terms of value of deals, M&A was the leading deal category in the US medical devices industry with total deals worth $1.04bn, while venture financing and private equity deals totalled $769.28m and $725m, respectively.

US medical devices industry deals in December 2019: Top deals

The top five medical devices industry deals accounted for 70.8% of the overall value during December 2019.

The combined value of the top five medical devices deals stood at $1.8bn, against the overall value of $2.54bn recorded for the month.

The top five medical devices industry deals of December 2019 tracked by GlobalData were:

1) Altaris Capital Partners’s $650m private equity deal with 3M

2) The $525m acquisition of Clinical Innovations by Laborie Medical Technologies

3) Boston Scientific’s $275m acquisition of Channel Medsystems

4) The $221.34m acquisition of AvKare by Amneal Pharmaceuticals

5) Foresite Capital Management, JS Capital Management, Merieux Developpement, MLS Capital Fund II, NanoDimension Management, Oak HC/FT Partners, Paladin Capital Group and Venrock’s venture financing of Inscripta for $125m.

Verdict deals analysis methodology

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.